By Michael Susin
Belluscura PLC said Friday that it expects to report an Ebitda loss for 2022 in line with market expectations.
The developer of medical devices didn’t provide any figures, but said that adjusted loss before interest, taxes, depreciation and amortization–which strips out exceptional and other one-off items–for the year is anticipated to be in line with views.
Retained cash balances are expected to be at $1.8 million.
The company shipped 1,226 units of its X-PLOR product by Dec. 31, compared with 377 units shipped in 2021, it added.
“We have enhanced our production, quality accreditation and supply chain…as we expand our distribution partners and geographical reach. Market reception for the next generation X-PLOR and Nomad App has been extremely positive, with an encouraging level of forward orders,” Chief Executive Robert Rauker said.
Write to Michael Susin at michael.susin@wsj.com
Read More: Belluscura Sees 2022 Loss in Line With Market Views